

Clinical trials of AKT Inhibitors for advanced breast cancer (metastatic) in HR+HER2-

TrialResults-center www.trialresultscenter.org

1 Akt inhibitor

Trial	Treatments	Patients	Trials design and methods
AZD2014 + FUL vs lulvestrant alone			
MANTA <i>ongoing</i> [NCT02216786] n=NA follow-up:	Fulvestrant + AZD2014 (continuous daily schedule) or Fulvestrant + AZD2014 (intermittent schedule - 2 days on, 5 days off) versus Fulvestrant or Fulvestrant + everolimus	patients with ER-positive, HER2-negative advanced or metastatic breast cancer, whose disease relapsed during treatment with (or within 12 months after discontinuation of) an AI in the adjuvant setting or progressed during treatment with an AI in the metastatic setting	
AZD5363 + wPTXweekly paclitaxel vs weekly paclitaxel			
BEECH <i>ongoing</i> [NCT01625286] n=NA follow-up:	AZD5363 in combination with paclitaxel versus placebo in combination with paclitaxel	patients with estrogen receptor-positive advanced or metastatic breast cancer, including a subgroup who have the phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) tumour mutation	

References

MANTA, :

BEECH, :

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.